Positron emission tomography in Parkinson's disease: insights into impulsivity
- PMID: 29206483
- PMCID: PMC6410706
- DOI: 10.1080/09540261.2017.1398139
Positron emission tomography in Parkinson's disease: insights into impulsivity
Abstract
This study reviews previous studies that employ positron emission tomography (PET) imaging assessments in Parkinson's disease (PD) patients with and without Impulsive Compulsive Behaviours (ICB). This begins with a summary of the potential benefits and limitations of commonly utilized ligands, specifically D2/3 receptor and dopamine transporter ligands. Since previous findings emphasize the role of the ventral striatum in the manifestation of ICBs, this study attempts to relate these imaging findings to changes in behaviour, especially emphasizing work performed in substance abuse and addiction. Next, it reviews how increasing disease duration in PD can influence dopamine receptor expression, with an emphasis on differential striatal and extra-striatal changes that occur along the course of PD. Finally, it focuses on how extra-striatal changes, particularly in the orbitofrontal cortex, amygdala, and anterior cingulate, may influence the proficiency of behavioural regulation in PD. The discussion emphasizes the interaction of disease and medication effects on network-wide changes that occur in PD, and how these changes may result in behavioural dysregulation.
Keywords: PET imaging; Parkinson’s disease; dopamine receptors; impulse control; ventral striatum.
Conflict of interest statement
Disclosure statement
D.C. has received personal fees from AbbVie, Acadia, Huntington Study Group, Lundbeck, Neurocrine, Teva Neuroscience, outside of submitted work. A.S. has no conflicts of interest.
Similar articles
-
Nigrostriatal and Mesolimbic D2/3 Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors.J Neurosci. 2018 Mar 28;38(13):3230-3239. doi: 10.1523/JNEUROSCI.3082-17.2018. Epub 2018 Feb 26. J Neurosci. 2018. PMID: 29483278 Free PMC article.
-
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487. Brain. 2022. PMID: 34951464 Free PMC article. Clinical Trial.
-
Accentuated Paralimbic and Reduced Mesolimbic D2/3-Impulsivity Associations in Parkinson's Disease.J Neurosci. 2023 Dec 13;43(50):8733-8743. doi: 10.1523/JNEUROSCI.1037-23.2023. J Neurosci. 2023. PMID: 37852792 Free PMC article.
-
Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.Int Rev Neurobiol. 2018;141:365-404. doi: 10.1016/bs.irn.2018.07.030. Epub 2018 Aug 13. Int Rev Neurobiol. 2018. PMID: 30314604 Review.
-
Identifying the Basic Dimensions of Medication-Triggered Impulsive Compulsive Behaviours in Parkinson's Disease.Eur Neurol. 2023;86(2):81-84. doi: 10.1159/000528900. Epub 2023 Jan 19. Eur Neurol. 2023. PMID: 36657405 Review.
Cited by
-
Self-reported rates of impulsivity in Parkinson's Disease.Ann Clin Transl Neurol. 2020 Apr;7(4):437-448. doi: 10.1002/acn3.51016. Epub 2020 Mar 29. Ann Clin Transl Neurol. 2020. PMID: 32227451 Free PMC article.
-
Artificial Intelligence and Neuroscience: Transformative Synergies in Brain Research and Clinical Applications.J Clin Med. 2025 Jan 16;14(2):550. doi: 10.3390/jcm14020550. J Clin Med. 2025. PMID: 39860555 Free PMC article. Review.
References
-
- Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, & Leenders KL (1994). [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology, 44, 1325–1329. doi:10.1212/WNL.44.7.1325 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical